Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-03-09 20:57:57 ET
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call March 9, 2026 4:30 PM EDT
Company Participants
Carrie Graham - Vice President of Investor Relations & Advocacy
Dennis Lanfear - Chairman, President & CEO
Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board
Rosh Dias - Chief Medical Officer
Sameer Goregaoker - Chief Commercial Officer
Bryan McMichael - Chief Financial Officer
...
Read the full article on Seeking Alpha
For further details see:
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus BioSciences Inc.
NASDAQ: CHRS
CHRS Trading
1.05% G/L:
$1.93 Last:
1,799,290 Volume:
$1.86 Open:
CHRS Latest News
March 09, 2026 04:15:00 pm
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 02, 2026 09:30:00 am
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
February 17, 2026 04:11:28 pm
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
CHRS Stock Data
$262,894,453
111,104,635
0.81%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
